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Abstract 
Background: Over the past two decades, Uganda has experienced a significant increase in clinical research driven by 
both academia and industry. This has been combined with a broader spectrum of research proposals, with respect to 
methodologies and types of intervention that need evaluation by Research Ethics Committees (RECs) with associated 
increased requirement for expertise. We assessed the competencies of REC members regarding review of research 
protocols with complex and emerging research study designs. The aim was to guide development of a training cur‑
riculum to improve the quality of scientific and ethical review.
Methods: This was a cross‑sectional study design, with quantitative data collection methods. Research Ethics 
Committee members completed a structured pre‑coded questionnaire on current competence with complex and 
emerging study design. REC members were asked to outline a list of additional topics for which they needed training. 
Data from coded questions were entered into Epidata Version 3.1 and then exported to STATA Version14.1 for analysis. 
Descriptive analysis was performed and findings are presented using percentages and frequencies.
Results: We enrolled 55 REC members from 6 RECs who have a total of 97 members. The majority of whom were 
males (56.4%, n = 31/55). The level of competence for review of selected study design was lowest for Controlled 
Human Infection Model (10.9%, n = 6) and reverse pharmacology design (10.9%, n = 6), and highest for cluster rand‑
omized study design (52.7%, n = 29) and implementation science research (52.7%, n = 29).
Conclusion: Competence for review of research protocols with complex and emerging study design was low among 
participating REC members. We recommend prioritising training of REC members on complex and emerging study 
designs to enhance quality of research protocol review.
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Background
Clinical research remains cardinal in advancing knowl-
edge of disease, human biology, behavior and informs 
our health care practice [1]. In Uganda, there has been 
an up surge in clinical research driven by both academia 
Open Access
*Correspondence:  pbyakika@gmail.com
1 Infectious Diseases Institute, Makerere University, College of Health 
Sciences, P.O BOX 22418, Kampala, Uganda
Full list of author information is available at the end of the article
Page 2 of 7Ainembabazi et al. BMC Med Ethics          (2021) 22:132 
and industry. Much of this focuses on the need to combat 
the emergence and re-emergence of infectious disease 
epidemics; including HIV, hemorrhagic fevers, tubercu-
losis, malaria, neglected tropical diseases, non-commu-
nicable diseases and the recent Severe Acute Respiratory 
Syndrome Corona Virus-2 that causes Corona virus dis-
ease-19 (COVID-19) [2–5]. This has broadened the spec-
trum of research activities in the quest for solutions to 
improve health and wellbeing.
Health research practice in Uganda has evolved over 
the years from mostly observation studies to more com-
plex clinical interventional research. Documented early 
research using observational study designs focused on 
measuring incidence, prevalence and describing presen-
tation of diseases. For example, Zika virus in 1947 and 
1948, Burkitt’s lymphoma in the 1960s, Buruli ulcer in 
the early 1960s, Busoga hernia in 1964 and HIV/AIDs in 
the late 1980s [6–10].
With the coming of the HIV pandemic and intro-
duction of antiretroviral therapy, scientists in Uganda 
embarked on conducting clinical trials with adherence 
and long-term efficacy monitoring [11, 12]. Recently, 
there has been increasing interest in vaccines research 
for infectious diseases and research for a cure for HIV 
[13] and more recently, COVID-19.
This research, which aimed to develop novel preven-
tive, investigational and treatment strategies, is complex 
in design and involves significant ethical challenges—
hence the need for competence to achieve high quality 
review and monitoring by Research Ethics Committees 
(REC) members, for knowledge generation while assur-
ing for safety and wellbeing of humans as research 
participants.
Uganda’s research regulatory process mandates the 
RECs to review the science and ethics of research propos-
als, approve research protocols and oversee the conduct 
of clinical research with the aim of promoting high qual-
ity scientific research while minimizing risk to humans 
and ensuring respect for the research participant’s rights, 
values and interests [14].
Uganda has twenty-six [26] RECs accredited by the 
Uganda National Council for Science and Technology 
(UNCST). The REC accreditation is valid for three (3) 
years and is subject to continuing compliance with all 
applicable national standards and guidelines for RECs in 
Uganda, and to any additional stipulations or guidelines 
that may be provided by the UNCST [14].
RECs have mostly been reviewing observational stud-
ies since they are commonly conducted among studies 
approved at IDI Scientific Review committee between 
2004 and 2017, observational studies make up 45%, clini-
cal trials 19% and other types of research account for only 
25%. Within clinical trials 59% are phase IV, 27% phase 
III and only 14% phase I/II (mostly vaccines) [15]. In a 
study conducted on academic research productivity of 
post-graduate students at Makerere University College 
of Health Sciences, Uganda, from 1996 to 2010, 75% of 
the post-graduate research projects were cross-sectional 
studies, with the least common designs being randomised 
trials (5%), diagnostic accuracy (3%) and economic evalu-
ation (1%) [16]. However, there is increased conduct of 
clinical trials including phase I and II according to the 
National Drug Authority clinical trials website [16, 17].
Challenges arise when RECs are presented with pro-
tocols which stretch their expertise. The adaptation of 
complex and emerging research methods needs matched 
expertise by the REC members in order to conduct effi-
cient and high quality scientific and ethical review.
It is therefore important to ensure that members of 
RECs have the competence to review research protocols 
to protect the safety, rights and welfare of research par-
ticipants while advancing knowledge through high qual-
ity research. This study aimed to assess the competencies 
of REC members regarding review of research protocols 
with complex and emerging research study designs, in 
order to guide development of a relevant training cur-
riculum for REC members.
Methods
Study design, site and population
This was a cross-sectional study among REC members 
from 6 UNCST accredited RECs located in Makerere 
University College of Health Sciences (MAKCHS) and 
Mulago National Referral Hospital, and Uganda Can-
cer Institute. The 6 RECs included; 4 RECs from each 
school of MAKCHS; School of Health Sciences REC 
(SHSREC), School of Medicine REC(SOMREC), School 
of Biomedical Sciences REC (SBSREC), School of Public 
Health Sciences REC (SPHREC), and the 2 were Mulago 
Hospital REC (MHREC) and Uganda Cancer Institute 
REC (UCIREC). The REC composition is guided by the 
UNSCT with the membership of 13–20 each. All REC 
members were eligible to enrol into the study if they were 
willing to participate.
Study procedures
We planned to conduct face-face interviews with paper-
based questionnaires, however, due to the lock-down 
restrictions following the COVID-19 pandemic, we 
changed to an online survey using the KoBoToolbx. 
The lists of REC members were obtained from the REC 
administrators with contact details: email and tele phone 
number. An email with a link to the online Informed 
Consent Form and the survey questionnaire were sent to 
all REC members inviting them to participate in the sur-
vey. In order to increase on the response rate, email and 
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telephonic reminders were sent for participants who had 
not filled the survey after 7 and at 14 days of sending the 
questionnaire.
Data collection
Data were collected using a pre-coded questionnaire in 
English language (Additional file  1). The questionnaire 
consisted of questions on demographic characteristics 
and self-reported competence in review of research pro-
tocols with complex and emerging study designs. The 
list of complex and emerging study design was gener-
ated from a consultative meeting with the REC chair-
persons of the six RECs and reviewed by the study team 
and the study advisory board. Complex study design in 
this study referred to conventional research designs that 
apply methodologies that are not easy to design, ana-
lyse or understand. The complex study designs assessed 
included; adaptive, ecological, phase I, phase II, imple-
mentation science, step wedged design, and cluster ran-
domized design. Emerging study design in this study 
referred to research designs that are increasingly being 
applied by researchers in the conduct of research in the 
low- and middle-income countries. The emerging study 
designs assessed included; controlled human infection 
model, reverse pharmacological design, and evaluation 
of studies on new technology/devices. The questions 
assessing the competence were on a Likert scale with four 
alternative responses with 1 = not competent, 2 = some-
what competent, 3 = competent, 4 = very competent. 
We used open-ended questions to collect data on other 
study designs that were not included on the list and asked 
for additional topics for which they needed training. 
The study coordinator checked the questionnaires for 
completeness.
Data management and analysis
Data were entered into the study data base developed 
using Epi data version 3.1 released by Epi data Asso-
ciation, Odense, Denmark with in-built quality control 
checks. The final dataset was exported to STATA version 
14.1 released by StataCorp for analysis. Competence of 
REC members was further categorized into two: compe-
tent and not competent and summarized using frequen-
cies and percentages.
Ethical consideration
The study was approved by School of Medicine REC 
(study reference number: #REC REF 2020-024), which 
is affiliated to Makerere University and accredited by 
UNCST (accreditation number: IRB00002062). The 
study also received approval from UNCST (study refer-
ence number: HS542ES). The REC chairpersons were 
informed about the survey before administering the 
questionnaire to REC members and Informed consent 
was obtained from each participant before administering 
the questionnaire.
Results
Social demographic characteristics of the participants
A total of 55 out of the 97 REC members contacted com-
pleted the survey questionnaire, giving a 56.7% response 
rate. All participants (23/23, 100%) that were contacted 
physically while 32 out of 74 participants contacted 
through email completed the survey. Of the 55 partici-
pants, 56.4% were male. Participants were from diverse 
background including; social sciences, bioethics, epide-
miology and biostatistics, psychology, dentistry, educa-
tion, medicine, oncology, public health, basic sciences, 
nursing and pharmacy as shown in Table 1 below. Major-
ity of the participants had attained a Doctorate degree 
(PhD) (31/55, 56.4%). The highest number of participants 
from any REC was 14.
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Competency regarding review of research protocols
The level of competence for review of selected complex 
and emerging study designs was lowest for controlled 
human infection model (10.9%, n  =  6), reverse phar-
macology design (10.9%, n =  6), and highest for cluster 
randomized study design (52.7%, n = 29), and implemen-
tation science research (52.7%, n = 29). The proportions 
of REC members competent to review other assessed 
study designs are; evaluation of new technology and 
digital health interventions (21.8%, n = 12), step wedged 
design (29.1%, n = 16), phase II clinical trials (38.2%, 
n = 21), case control with advanced epidemiology (41.8%, 
n = 23), ecological study design ( 43.6%, n = 24), phase I 
clinical trials (43.6%, n = 24), and adaptive study design 
(45.5%, n = 25) as shown in Fig. 1.
Additional areas that pose challenges during review 
of research protocols
Some REC members reported difficulty reviewing 
research protocols for genetic studies; studies involving 
large longitudinal data, investigational new drug applica-
tions, new technology/devices, herbal medicine research 
as well as ethical dilemmas that arise with complex and 
emerging study designs.
Discussion
We assessed the competencies of REC members regard-
ing review of research protocols with complex and 
emerging research study designs to guide development 
of a relevant training curriculum to improve the quality 
of review. This study was initially designed to collect data 
using interviewer administered questionnaires, however, 
due to the COVID-19 pandemic and lockdown restric-
tions, we collected data using online self-administered 
questionnaires. Participants were from diverse back-
ground in line with the UNCST guidelines for composi-
tion of RECs in Uganda [14].
The response rate amongst REC members in this study 
was slightly higher compared to 52% in a similar study in 
a similar setting [18].
The majority of the participants reported lack of com-
petence to review research protocols with complex and 
emerging study designs. The UNCST guidelines for com-
position of a REC require diversity of background of REC 
members. The guidelines also provide for an option to 
co-opt expertise to review research protocols when the 
REC members do not have adequate competence, and 
joint reviews may be arranged for review of complex and 
emerging study designs [14]. This remedy was also pro-
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Fig. 1 Proportion of REC members competent in review of complex and emerging study designs
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strengthen REC review of highly innovative interventions 
in clinical trials [19]. Since REC members take full and 
collective responsibility to approve the research proto-
cols, they need to be competent. The lack of competence 
reported could be due to the presence of members with-
out an epidemiological background such as some social 
scientists and community representatives who are per-
manent members of the REC and without whom a REC 
review meeting cannot take place. Furthermore, there 
has been an increase in clinical interventional research 
driven by the changing disease patterns, emergence of 
new and highly infectious diseases plus the increased 
demand for research in emergency situations which pre-
sents more complex design and ethical challenges requir-
ing refresher training.
Difficulty in review of complex study designs has been 
documented elsewhere. Lack of expertise was cited in a 
systematic review as one of the barriers hindering con-
duct of clinical trials in developing countries, lack of 
expertise was one of the cited barriers to their imple-
mentation in developing countries [20]. Chapman et  al. 
highlighted that many RECs struggle with evaluating and 
providing oversight for innovative phase I trials because 
of lack of the technical competence to be able to conduct 
their own review [21].
Similar challenges were highlighted during the Global 
Forum on Bioethics in Research conferences [22] and 
the 10th Annual National Research Ethics Conference in 
Uganda [23]. The emergence of study designs like con-
trolled human infection model, studies with digital inter-
vention and genetic studies present enormous scientific 
and ethical challenges [24–26].
These challenges include establishing justification 
for deviating from the conventional trials, risk–benefit 
evaluation and informed consent. Stepped wedged trials 
and cluster randomised trial designs may need consid-
erable thoughts on issues of scientific validity, practical, 
and logistical justification [27]. As Spencer Hey and col-
leagues noted, “new trial designs present challenges for 
assessing equipoise and discussing risks with patients 
and participants” [28]. For example, stepped wedged 
design delay the roll-out of the intervention to some of 
the control groups, the risks of delaying the roll-out 
should be considered [29]. In controlled human infection 
model studies, risk–benefit evaluation could be highly 
challenging since the interventions are tested on health 
volunteers that don’t stand to benefit clinically from the 
research [30].
The lack of competence in review of research protocols 
with complex and emerging study designs could lead to 
a longer or delayed research review process, poor qual-
ity review and rejection of important studies due to 
reluctance by the REC members to take on responsibility 
for novel trials being conducted in the country since all 
approved research projects must be monitored to com-
pletion. In addition, it may result in disinclination of 
many REC members to question the quality of the sci-
entific data and their potential social value [31]. Instead, 
they may be inclined to defer to the judgment of one 
expert member rather than carefully scrutinizing the sci-
entific rigour and ethical considerations for the protocols 
being presented.
Limitations of the study
The small sample size which we attribute to the impact 
of COVID-19 restrictive measures affected our analysis 
and conclusions. All participants who were contacted in 
person completed the survey compared to 43% of those 
contacted through email filled the online survey. This 
indicates that response rate to the survey was greatly 
affected by the change in the mode of data collection 
because of COVID-19 restrictive prevention measures. 
This is consistent with previous studies that concluded 
that online surveys generally have a lower response rate 
compared to the in-person surveys [32, 33]. Few par-
ticipants responded to the open-ended question and 
therefore this information could not be presented in the 
results as percentages. The results may not be generalisa-
ble to all RECs in the country due to the highly academic 
environment of the six RECs. There is limited literature 
on assessment of competence in assessed complex and 
emerging study designs amongst REC members in other 
settings. Thus, it is difficult to compare our findings to 
other places.
Conclusion and recommendation
There is lack of competence in review of complex and 
emerging study design among the REC members studied 
and additional training in this area is an urgent prior-
ity. Results of this study have been used to guide devel-
opment of a training curriculum for REC members in 
Uganda. The curriculum includes training on introduc-
tion to randomised controlled trials, phase I-IV clinical 
trials, adaptive study design, cluster randomized trial 
design, stepped wedged trial design, ecological study 
design, Implementation Science Research, controlled 
human infection model, reverse pharmacological design, 
and evaluation of studies with new technology/devices. 
Each session highlights key design issues, scientific and 
ethical issues that a REC member should pay attention.
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